Arcturus Therapeutics (ARCT) Receives New Coverage from Analysts at Chardan Capital

Equities researchers at Chardan Capital began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note issued to investors on Monday. The firm set a “buy” rating and a $12.00 price target on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 31.15% from the company’s current price.

Other equities analysts have also issued research reports about the company. Ladenburg Thalmann Financial Services assumed coverage on Arcturus Therapeutics in a research note on Wednesday, November 29th. They issued a “buy” rating on the stock. Zacks Investment Research upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Wednesday, October 4th. Roth Capital lowered Arcturus Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $4.00 to $1.00 in a research note on Friday, September 29th. Finally, WBB Securities upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $3.08.

Arcturus Therapeutics (ARCT) opened at $9.15 on Monday. Arcturus Therapeutics has a 52 week low of $6.51 and a 52 week high of $15.19. The company has a market capitalization of $96.71, a price-to-earnings ratio of -2.29 and a beta of 1.55.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). analysts forecast that Arcturus Therapeutics will post -0.81 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Arcturus Therapeutics (ARCT) Receives New Coverage from Analysts at Chardan Capital” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://sportsperspectives.com/2018/01/22/arcturus-therapeutics-arct-receives-new-coverage-from-analysts-at-chardan-capital.html.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply